NewAmsterdam Pharma Company NAMS Net unrealized gains (losses) on securities still held
Net unrealized gains (losses) on securities still held at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's net unrealized gains (losses) on securities still held.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's net unrealized gains (losses) on securities still held?
- NewAmsterdam Pharma Company (NAMS) reported net unrealized gains (losses) on securities still held of -$572K in Q1 2026.
- How has NewAmsterdam Pharma Company's net unrealized gains (losses) on securities still held changed year-over-year?
- NewAmsterdam Pharma Company's net unrealized gains (losses) on securities still held decreased by 1633.3% year-over-year, from -$33K to -$572K.
- What does net unrealized gains (losses) on securities still held mean?
- This metric measures the change in the market value of investment securities held by the company that have not yet been sold. It reflects unrealized gains or losses that are excluded from net income and instead reported as a component of other comprehensive income. This provides insight into the performance of the company's treasury or investment portfolio outside of core operational activities.